Basic/Clinical Science Session

Hope on the Horizon: Novel Therapeutics for Glomerular Disease, Including the Michelle P. Winn, MD, Endowed Lectureship

November 08, 2019 | 02:00 PM - 04:00 PM

Location: Ballroom A, Walter E. Washington Convention Center

Session Description

Validated therapeutic targets for glomerular disease are lacking with no clinically available therapies approved by the US Food and Drug Administration. Recent advances in understanding the molecular pathogenesis of glomerulopathies has raised the prospect of therapeutic drug development. This session covers recent promising discoveries that augur well for novel treatment options.

ASN gratefully acknowledges Duke University School of Medicine, the school's Division of Nephrology, and several individuals for support of the Michelle P. Winn, MD, Endowed Lectureship.

Learning Objective(s)

  • Describe recent advances in the understanding of glomerular disease pathogenesis
  • Discuss strategies for using genome-wide association studies to identify targets to treat glomerular disease
  • Describe precision-based therapeutic approaches to glomerular disease

Learning Pathway(s)

  • Glomerular Diseases
  • Genetic Diseases of the Kidneys

Moderators

  • Markus Bitzer, MD
  • Shuta Ishibe, MD

Presentations

  • Mechanism-Based Precision Therapeutics for Proteinuric Kidney Disease
    02:00 PM - 02:30 PM
    Anna Greka, MD, PhD
  • Novel Targets and Approaches to Alport Syndrome
    02:30 PM - 03:00 PM
    Alessia Fornoni, MD, PhD, FASN
  • Genome-Wide Association Study (GWAS)-Derived Targets for Glomerular Diseases, The Michelle P. Winn, MD, Endowed Lectureship
    03:00 PM - 03:30 PM
    Rasheed A. Gbadegesin, MD, MBBS, FASN 
  • Small Molecule Inhibitors to Treat Steroid-Resistant Nephrotic Syndrome
    03:30 PM - 04:00 PM
    Moin Saleem, MD, MBBS, PhD